Developer docs
API playgroundTry for free, no card

Search company profiles

Quoin Pharmaceuticals

Full company profile

uuid0004cda

Namestring
Quoin Pharmaceuticals
Legal namestring
Quoin Pharmaceuticals, Inc.
Websiteurl
quoinpharma.com
Company typeenum
Public
Founded yearint
2021
Descriptiontext

Quoin Pharmaceuticals (NASDAQ: QNRX) is a clinical-stage specialty pharmaceutical company developing therapeutic products for rare and orphan skin diseases, headquartered in Ashburn, Virginia. Its pipeline comprises three distinct product candidates. The lead asset, QRX003 (proposed brand name QYLEKI), is a topical lotion containing a broad-spectrum serine protease inhibitor formulated with a proprietary polymer delivery technology licensed from Skinvisible's Invisicare system; the active ingredient functionally replaces the missing LEKTI protein in patients with SPINK5 gene mutations, down-regulating Kallikrein hyperactivity to normalize skin shedding and strengthen the skin barrier. QRX003 is in pivotal Phase 3 development for Netherton Syndrome, with additional INDs/plans for Peeling Skin Syndrome, SAM Syndrome, and Ichthyosis. QRX008 is a small-molecule VLA-4 inhibitor in early development for Scleroderma, with proof of concept demonstrated in the Tsk1/+ mouse model. QRX009 is a proprietary topical rapamycin formulation (4% lotion, 5% dermal patch) targeting Microcystic Lymphatic Malformations, Venous Malformations, and Angiofibromas, with planned investigator-led studies in Pachyonychia Congenita, Gorlin Syndrome, and Tuberous Sclerosis Complex.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersAshburn, United States
HQ citystring
Ashburn
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rare disease therapeutics, specialty pharmaceuticals, orphan drug development, topical drug delivery, clinical-stage biopharmaceuticals
Industry1 code
PRIMARYHLAIACAL
Dermatology Specialty Pharmaceuticals
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Pharmaceuticals — Rare Disease Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Product Sales (Future)
TypeOne Time License
Description

Quoin Pharmaceuticals is a late clinical-stage specialty pharmaceutical company. It does not yet have approved products generating revenue. Its business model is premised on developing and commercializing therapeutic drug products for rare and orphan diseases, with the expectation of generating revenue through product sales upon regulatory approval. The company has received Orphan Drug Designation in the US, EU, and Japan for QRX003, which provides potential market exclusivity benefits upon approval.

quoinpharma.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1QYLEKI
Description

Proposed brand name for investigational drug QRX003 for Netherton Syndrome

stocktitan.net
+1 more record
Core offering1 text field

Quoin Pharmaceuticals is a clinical-stage specialty pharmaceutical company developing topical and small-molecule therapeutics for rare and orphan skin and connective tissue diseases. Its lead candidate QRX003 (QYLEKI) is a broad-spectrum serine protease inhibitor lotion in pivotal Phase 3 trials for Netherton Syndrome, with additional development in Peeling Skin Syndrome, SAM Syndrome, and Ichthyosis. The pipeline also includes QRX008 (a VLA-4 small-molecule inhibitor for Scleroderma) and QRX009 (a proprietary topical rapamycin lotion and dermal patch for vascular malformations and related skin disorders). None of these products are yet approved; commercial revenue is expected from future product sales supported by a mix of direct sales infrastructure and international distribution partnerships.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 4 out of 6 pediatric Netherton Syndrome patients (under 10 years of age) showed 'Improved' or 'Significantly Improved' status across key clinical endpoints
+5 more records
Product overview1 text field

Quoin Pharmaceuticals is a clinical-stage specialty pharmaceutical company developing therapeutic products for rare and orphan diseases. The company operates a pipeline of three distinct product candidates: QRX003 (QYLEKI), a topical serine protease inhibitor lotion for Netherton Syndrome and related skin disorders; QRX008, a VLA-4 inhibitor for Scleroderma; and QRX009, a topical rapamycin formulation for vascular and skin malformations. The company has established international marketing and distribution partnerships covering 61 countries and plans internal commercial infrastructure for the US, Western Europe, and Japan markets.

Product and service3 records
1QRX003 (proposed brand: QYLEKI)
CategorySpecialty pharmaceutical — topical broad-spectrum serine protease inhibitor lotion for rare skin diseases (Netherton Syndrome lead indication)
Description

QRX003 is a topical lotion comprised of a broad-spectrum serine protease inhibitor formulated with proprietary delivery technology (Invisicare polymer delivery system licensed from Skinvisible, Inc.). The active ingredient performs the function of the missing LEKTI protein and down-regulates Kallikrein hyperactivity, leading to normalized skin shedding and a stronger skin barrier. The lead indication is Netherton Syndrome (a rare genetic skin disorder caused by SPINK5 mutations with a 10-20% newborn mortality rate and no approved treatment); additional indications include Peeling Skin Syndrome, SAM Syndrome, and Ichthyosis. It is being studied in pediatric and adult patients via two FDA-cleared pivotal whole-body clinical studies and an open IND.

2QRX008
CategorySpecialty pharmaceutical — VLA-4 small-molecule inhibitor for Scleroderma
Description

QRX008 is a small-molecule VLA-4 inhibitor being developed for the treatment of Scleroderma (systemic sclerosis). It uses small-molecule inhibitors to disrupt the VCAM-1:VLA-4 interaction, a key process controlling immune cell migration into inflamed tissue. Proof of concept has been demonstrated with VLA-4 inhibition in the Tsk1/+ mouse model of Scleroderma.

3QRX009
CategorySpecialty pharmaceutical — topical rapamycin (sirolimus) lotion and dermal patch for rare vascular and skin malformations
Description

QRX009 is a proprietary topical formulation of rapamycin (sirolimus) designed to optimize local skin penetration and deliver rapamycin directly to affected dermal layers. The company achieved target loadings of 4% rapamycin in its topical lotion and 5% in its dermal patch delivery systems. It is being developed for rare vascular and skin malformations including Microcystic Lymphatic Malformations, Venous Malformations, and Cutaneous Angiofibromas, with planned investigator-led clinical studies in Pachyonychia Congenita, Gorlin Syndrome, and Tuberous Sclerosis Complex.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership16 partners
1Professor Edel O'Toole, Queen Mary University of London
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-28
Description

Professor Edel O'Toole of Queen Mary University of London is leading an investigator-initiated clinical study for QRX009 in Pachyonychia Congenita, planned for Q3 2026. This is one of several investigator-led clinical studies Quoin is planning for QRX009 across multiple indications.

quoinpharma.com
2Undisclosed Canadian Partner
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-07-01
Description

Commercialization agreement signed for Canadian market in July 2022.

quoinpharma.com
3Undisclosed Greater China Partner
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-06-01
Description

Distribution agreement covering Greater China signed June 2022.

quoinpharma.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-05-01
Description

Second exclusive research agreement with QUT (May 2022) for scleroderma treatment. Additionally, a funding agreement (November 2021) supported preclinical investigation of a bi-functional protein at QUT.

5Undisclosed Middle East / North Africa / Australasia Partners
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-02-01
Description

Exclusive distribution agreements signed covering the Middle East, North Africa, and Australasia in November 2021.

quoinpharma.com
6Undisclosed Israel and European Partners
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-02-01
Description

Marketing partnerships for distribution of QRX003 in Israel and to 21 European countries signed February 2022.

quoinpharma.com
7Undisclosed Latin America Partner
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-01-01
Description

Exclusive distribution agreement for key Latin America markets signed January 2022 as part of international expansion covering 61 countries.

quoinpharma.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-11-01
Description

Quoin signed a research agreement with University College Cork in Ireland in June 2024 to support the scleroderma treatment program (QRX008). Additionally, an earlier funding agreement (November 2021) supported preclinical investigation of a bi-functional protein at QUT. CEO Dr. Michael Myers earned his Ph.D. in Chemistry from University College Cork.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-11-01
Description

Distribution partner covering Australasia region as part of nine separate strategic commercial agreements spanning 61 countries.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-11-01
Description

Distribution partner (logo shown on company website) as part of nine strategic commercial agreements spanning 61 countries.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-11-01
Description

Distribution partner (logo shown on company website) as part of nine strategic commercial agreements spanning 61 countries.

12Neopharm
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-11-01
Description

Distribution partner (logo shown on company website) as part of nine strategic commercial agreements spanning 61 countries.

quoinpharma.com
13GenPharm
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-11-01
Description

Distribution partner (logo shown on company website) as part of nine strategic commercial agreements spanning 61 countries.

quoinpharma.com
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-11-01
Description

Distribution partner (logo shown on company website) as part of nine strategic commercial agreements spanning 61 countries.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-11-01
Description

Distribution partner (logo shown on company website) as part of nine strategic commercial agreements spanning 61 countries.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-11-01
Description

Distribution partner (logo shown on company website) as part of nine strategic commercial agreements spanning 61 countries.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Clinical-stage immunology company developing therapeutics for inflammatory diseases. Comparable in immunology/inflammation mechanism focus, though broader therapeutic area beyond dermatology.

TypeDirect peer
Description

Clinical-stage dermatology company developing therapeutics for skin diseases including rare immuno-dermatology indications. Similar size and stage profile to Quoin with comparable specialty-pharma GTM.

TypeBroad incumbent
Description

Larger rare-disease-focused biopharma with multiple programs across genetic conditions. Less directly comparable as a broader portfolio player, but operates in the same orphan-disease commercial and regulatory paradigm.

TypeDirect peer
Description

Specialty dermatology pharmaceutical company developing topical treatments for inflammatory skin diseases. Comparable in therapeutic area (medical dermatology), topical delivery focus, and rare/orphan indications.

TypeDirect peer
Description

Commercial-stage rare-disease dermatology biotech whose lead product Vyjuvek treats dystrophic epidermolysis bullosa. Closest analog to Quoin: rare genetic skin disease, topical/biologics platform, multi-jurisdiction orphan strategy, small public-company scale.

TypeBroad incumbent
Description

Established rare-disease biopharma with multiple approved orphan drugs across genetic conditions. Much larger scale but exemplifies the commercial model Quoin is targeting in Netherton Syndrome.

TypeEmerging player
Description

Late clinical-stage biotech developing therapies for rare genetic dermatological diseases including epidermolysis bullosa. Direct overlap in rare skin disease orphan-drug strategy.

TypeDirect peer
Description

Specialty dermatology company with FDA-approved topical products for skin conditions including rare indications. Comparable business model: small-cap, focused on topical treatments for dermatological diseases.

TypeDirect peer
Description

Dermatology-focused biopharma developing topical therapeutics for skin diseases. Comparable in topical-dermatology development focus and orphan/specialty positioning.

TypeDirect peer
Description

Previously independent rare-disease dermatology company (acquired by Chiesi in 2023) focused on epidermolysis bullosa and other rare skin conditions. Direct peer pre-acquisition in rare dermatology orphan-drug commercial strategy.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Quoin Pharmaceuticals

Specialty Pharmaceuticals — Rare Disease Therapeuticsquoinpharma.com

What Quoin Pharmaceuticals does

Quoin Pharmaceuticals (NASDAQ: QNRX) is a clinical-stage specialty pharmaceutical company developing therapeutic products for rare and orphan skin diseases, headquartered in Ashburn, Virginia. Its pipeline comprises three distinct product candidates. The lead asset, QRX003 (proposed brand name QYLEKI), is a topical lotion containing a broad-spectrum serine protease inhibitor formulated with a proprietary polymer delivery technology licensed from Skinvisible's Invisicare system; the active ingredient functionally replaces the missing LEKTI protein in patients with SPINK5 gene mutations, down-regulating Kallikrein hyperactivity to normalize skin shedding and strengthen the skin barrier. QRX003 is in pivotal Phase 3 development for Netherton Syndrome, with additional INDs/plans for Peeling Skin Syndrome, SAM Syndrome, and Ichthyosis. QRX008 is a small-molecule VLA-4 inhibitor in early development for Scleroderma, with proof of concept demonstrated in the Tsk1/+ mouse model. QRX009 is a proprietary topical rapamycin formulation (4% lotion, 5% dermal patch) targeting Microcystic Lymphatic Malformations, Venous Malformations, and Angiofibromas, with planned investigator-led studies in Pachyonychia Congenita, Gorlin Syndrome, and Tuberous Sclerosis Complex.

Quoin Pharmaceuticals firmographics

Firmographics
Name
Quoin Pharmaceuticals
Legal name
Quoin Pharmaceuticals, Inc.
Website
https://quoinpharma.com
Company type
Public
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Quoin Pharmaceuticals industry classification

Industry
Product category
Specialty Pharmaceuticals — Rare Disease Therapeutics
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAL
Dermatology Specialty Pharmaceuticals

Keywords

  • Rare disease therapeutics
  • Specialty pharmaceuticals
  • Orphan drug development
  • Topical drug delivery
  • Clinical-stage biopharmaceuticals

Where Quoin Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Ashburn
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Quoin Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Product Sales (Future): Quoin Pharmaceuticals is a late clinical-stage specialty pharmaceutical company. It does not yet have approved products generating revenue. Its business model is premised on developing and commercializing therapeutic drug products for rare and orphan diseases, with the expectation of generating revenue through product sales upon regulatory approval. The company has received Orphan Drug Designation in the US, EU, and Japan for QRX003, which provides potential market exclusivity benefits upon approval.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Quoin Pharmaceuticals product offering

Product offering

Core offering

Quoin Pharmaceuticals is a clinical-stage specialty pharmaceutical company developing topical and small-molecule therapeutics for rare and orphan skin and connective tissue diseases. Its lead candidate QRX003 (QYLEKI) is a broad-spectrum serine protease inhibitor lotion in pivotal Phase 3 trials for Netherton Syndrome, with additional development in Peeling Skin Syndrome, SAM Syndrome, and Ichthyosis. The pipeline also includes QRX008 (a VLA-4 small-molecule inhibitor for Scleroderma) and QRX009 (a proprietary topical rapamycin lotion and dermal patch for vascular malformations and related skin disorders). None of these products are yet approved; commercial revenue is expected from future product sales supported by a mix of direct sales infrastructure and international distribution partnerships.

Product overview

Quoin Pharmaceuticals is a clinical-stage specialty pharmaceutical company developing therapeutic products for rare and orphan diseases. The company operates a pipeline of three distinct product candidates: QRX003 (QYLEKI), a topical serine protease inhibitor lotion for Netherton Syndrome and related skin disorders; QRX008, a VLA-4 inhibitor for Scleroderma; and QRX009, a topical rapamycin formulation for vascular and skin malformations. The company has established international marketing and distribution partnerships covering 61 countries and plans internal commercial infrastructure for the US, Western Europe, and Japan markets.

Differentiator

Problem solved

Functional benefit

Brands

  • QYLEKI: Proposed brand name for investigational drug QRX003 for Netherton Syndrome
  • NETHERTON NOW

Products and services

  • QRX003 (proposed brand: QYLEKI) QRX003 is a topical lotion comprised of a broad-spectrum serine protease inhibitor formulated with proprietary delivery technology (Invisicare polymer delivery system licensed from Skinvisible, Inc.). The active ingredient performs the function of the missing LEKTI protein and down-regulates Kallikrein hyperactivity, leading to normalized skin shedding and a stronger skin barrier. The lead indication is Netherton Syndrome (a rare genetic skin disorder caused by SPINK5 mutations with a 10-20% newborn mortality rate and no approved treatment); additional indications include Peeling Skin Syndrome, SAM Syndrome, and Ichthyosis. It is being studied in pediatric and adult patients via two FDA-cleared pivotal whole-body clinical studies and an open IND.
  • QRX008 QRX008 is a small-molecule VLA-4 inhibitor being developed for the treatment of Scleroderma (systemic sclerosis). It uses small-molecule inhibitors to disrupt the VCAM-1:VLA-4 interaction, a key process controlling immune cell migration into inflamed tissue. Proof of concept has been demonstrated with VLA-4 inhibition in the Tsk1/+ mouse model of Scleroderma.
  • QRX009 QRX009 is a proprietary topical formulation of rapamycin (sirolimus) designed to optimize local skin penetration and deliver rapamycin directly to affected dermal layers. The company achieved target loadings of 4% rapamycin in its topical lotion and 5% in its dermal patch delivery systems. It is being developed for rare vascular and skin malformations including Microcystic Lymphatic Malformations, Venous Malformations, and Cutaneous Angiofibromas, with planned investigator-led clinical studies in Pachyonychia Congenita, Gorlin Syndrome, and Tuberous Sclerosis Complex.

Quantifiable outcome

  • 4 out of 6 pediatric Netherton Syndrome patients (under 10 years of age) showed 'Improved' or 'Significantly Improved' status across key clinical endpoints
  • +5 more outcomes

Companies that use Quoin Pharmaceuticals

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Quoin Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Quoin Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

16 partnerships are on record, tiered core and minor.

  • Professor Edel O'Toole, Queen Mary University of LondoncoreStrategic or Co-development Partner · 28 April 2026Professor Edel O'Toole of Queen Mary University of London is leading an investigator-initiated clinical study for QRX009 in Pachyonychia Congenita, planned for Q3 2026. This is one of several investigator-led clinical studies Quoin is planning for QRX009 across multiple indications.
  • Undisclosed Canadian PartnerminorChannel Partner/ Reseller/ Distributor · 1 July 2022Commercialization agreement signed for Canadian market in July 2022.
  • Undisclosed Greater China PartnerminorChannel Partner/ Reseller/ Distributor · 1 June 2022Distribution agreement covering Greater China signed June 2022.
  • Queensland University of Technology (QUT)coreStrategic or Co-development Partner · 1 May 2022Second exclusive research agreement with QUT (May 2022) for scleroderma treatment. Additionally, a funding agreement (November 2021) supported preclinical investigation of a bi-functional protein at QUT.
  • Undisclosed Middle East / North Africa / Australasia PartnersminorChannel Partner/ Reseller/ Distributor · 1 February 2022Exclusive distribution agreements signed covering the Middle East, North Africa, and Australasia in November 2021.
  • Undisclosed Israel and European PartnersminorChannel Partner/ Reseller/ Distributor · 1 February 2022Marketing partnerships for distribution of QRX003 in Israel and to 21 European countries signed February 2022.
  • Undisclosed Latin America PartnerminorChannel Partner/ Reseller/ Distributor · 1 January 2022Exclusive distribution agreement for key Latin America markets signed January 2022 as part of international expansion covering 61 countries.
  • University College Cork (UCC)coreStrategic or Co-development Partner · 1 November 2021Quoin signed a research agreement with University College Cork in Ireland in June 2024 to support the scleroderma treatment program (QRX008). Additionally, an earlier funding agreement (November 2021) supported preclinical investigation of a bi-functional protein at QUT. CEO Dr. Michael Myers earned his Ph.D. in Chemistry from University College Cork.
  • AFT PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 1 November 2021Distribution partner covering Australasia region as part of nine separate strategic commercial agreements spanning 61 countries.
  • WinHealthminorChannel Partner/ Reseller/ Distributor · 1 November 2021Distribution partner (logo shown on company website) as part of nine strategic commercial agreements spanning 61 countries.
  • Er-KimminorChannel Partner/ Reseller/ Distributor · 1 November 2021Distribution partner (logo shown on company website) as part of nine strategic commercial agreements spanning 61 countries.
  • NeopharmminorChannel Partner/ Reseller/ Distributor · 1 November 2021Distribution partner (logo shown on company website) as part of nine strategic commercial agreements spanning 61 countries.
  • GenPharmminorChannel Partner/ Reseller/ Distributor · 1 November 2021Distribution partner (logo shown on company website) as part of nine strategic commercial agreements spanning 61 countries.
  • OrPharm DCminorChannel Partner/ Reseller/ Distributor · 1 November 2021Distribution partner (logo shown on company website) as part of nine strategic commercial agreements spanning 61 countries.
  • OrPharmminorChannel Partner/ Reseller/ Distributor · 1 November 2021Distribution partner (logo shown on company website) as part of nine strategic commercial agreements spanning 61 countries.
  • Endo PharmaceuticalsminorChannel Partner/ Reseller/ Distributor · 1 November 2021Distribution partner (logo shown on company website) as part of nine strategic commercial agreements spanning 61 countries.

Scale indicators12 records

Recent moves7 records

Expansion highlights6 records

Quoin Pharmaceuticals competitors and assessment

Company assessment

Emerging players

  • AnaptysBio: Clinical-stage immunology company developing therapeutics for inflammatory diseases. Comparable in immunology/inflammation mechanism focus, though broader therapeutic area beyond dermatology.
  • Castle Creek Biosciences: Late clinical-stage biotech developing therapies for rare genetic dermatological diseases including epidermolysis bullosa. Direct overlap in rare skin disease orphan-drug strategy.

Direct peers

  • Aclaris Therapeutics: Clinical-stage dermatology company developing therapeutics for skin diseases including rare immuno-dermatology indications. Similar size and stage profile to Quoin with comparable specialty-pharma GTM.
  • Arcutis Biotherapeutics: Specialty dermatology pharmaceutical company developing topical treatments for inflammatory skin diseases. Comparable in therapeutic area (medical dermatology), topical delivery focus, and rare/orphan indications.
  • Krystal Biotech: Commercial-stage rare-disease dermatology biotech whose lead product Vyjuvek treats dystrophic epidermolysis bullosa. Closest analog to Quoin: rare genetic skin disease, topical/biologics platform, multi-jurisdiction orphan strategy, small public-company scale.
  • Sol-Gel Technologies: Specialty dermatology company with FDA-approved topical products for skin conditions including rare indications. Comparable business model: small-cap, focused on topical treatments for dermatological diseases.
  • Dermavant Sciences: Dermatology-focused biopharma developing topical therapeutics for skin diseases. Comparable in topical-dermatology development focus and orphan/specialty positioning.
  • Amryt Pharma: Previously independent rare-disease dermatology company (acquired by Chiesi in 2023) focused on epidermolysis bullosa and other rare skin conditions. Direct peer pre-acquisition in rare dermatology orphan-drug commercial strategy.

Broad incumbents

  • BridgeBio Pharma: Larger rare-disease-focused biopharma with multiple programs across genetic conditions. Less directly comparable as a broader portfolio player, but operates in the same orphan-disease commercial and regulatory paradigm.
  • BioMarin Pharmaceutical: Established rare-disease biopharma with multiple approved orphan drugs across genetic conditions. Much larger scale but exemplifies the commercial model Quoin is targeting in Netherton Syndrome.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Quoin Pharmaceuticals social profiles

Digital presence

Quoin Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Quoin Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles11 records

Quoin Pharmaceuticals subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Quoin Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Quoin Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Quoin Pharmaceuticals

What does Quoin Pharmaceuticals do?

Quoin Pharmaceuticals is a clinical-stage specialty pharmaceutical company developing topical and small-molecule therapeutics for rare and orphan skin and connective tissue diseases. Its lead candidate QRX003 (QYLEKI) is a broad-spectrum serine protease inhibitor lotion in pivotal Phase 3 trials for Netherton Syndrome, with additional development in Peeling Skin Syndrome, SAM Syndrome, and Ichthyosis. The pipeline also includes QRX008 (a VLA-4 small-molecule inhibitor for Scleroderma) and QRX009 (a proprietary topical rapamycin lotion and dermal patch for vascular malformations and related skin disorders). None of these products are yet approved; commercial revenue is expected from future product sales supported by a mix of direct sales infrastructure and international distribution partnerships.

Is Quoin Pharmaceuticals a public or private company?

Quoin Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was Quoin Pharmaceuticals founded?

Quoin Pharmaceuticals was founded in 2021. It employs 11 to 50 people.

Where is Quoin Pharmaceuticals based?

Quoin Pharmaceuticals is headquartered in Ashburn, United States, in the North America region.

How does Quoin Pharmaceuticals make money?

One revenue line is on record: product Sales (Future).

Who are Quoin Pharmaceuticals's main competitors?

Emerging players on record are AnaptysBio and Castle Creek Biosciences. Direct peers are Aclaris Therapeutics, Arcutis Biotherapeutics, Krystal Biotech, Sol-Gel Technologies, Dermavant Sciences and Amryt Pharma. Broad incumbents are BridgeBio Pharma and BioMarin Pharmaceutical.

Does Quoin Pharmaceuticals have an API?

No public API is recorded for Quoin Pharmaceuticals.

What industry is Quoin Pharmaceuticals in?

Quoin Pharmaceuticals's product category is Specialty Pharmaceuticals — Rare Disease Therapeutics. Its primary akta.pro industry code is HLAIACAL, Dermatology Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewCraig-Hallum initiates coverage of Quoin Pharmaceuticals at Buy, sets price target at $16Craig-Hallum initiated coverage of Quoin Pharmaceuticals at Buy with a price target of $16. The target implies an upside of 376.3% from the Nov 19 close of $3.36. The rating is not investment advice.TradingViewQuoin Pharmaceuticals Reports $4.9 Million Q3 Net Loss and Positive QRX003 Interim DataQuoin Pharmaceuticals reported a $4.9 million net loss for Q3 2026, with $33.2 million in cash and investments. The company announced positive interim results from its Phase 2/3 QRX003 study in Netherton Syndrome, with recruitment expected to complete by year-end 2026 and topline results in Q2 2027.Business & FinancialQuoin Pharmaceuticals' Latest NETHERTON NOW Video Details The Life Of A Family Living With Netherton SyndromeQuoin Pharmaceuticals released a NETHERTON NOW video featuring a family with Netherton Syndrome, detailing daily care and medical challenges. The company's investigational product QRX003 showed statistical significance in a Phase 2/3 trial, with full recruitment expected by end of 2026 and topline data in Q2 2027.GlobeNewswireQuoin Pharmaceuticals’ Latest NETHERTON NOW Video Details the Life of a Family Living with Netherton SyndromeQuoin Pharmaceuticals released a NETHERTON NOW video featuring Kristi Kristofferson and her daughter Kodi, who has Netherton Syndrome, and pediatric dermatologist Moise Levy. The video details Kodi's daily care, including painful baths and therapy, and highlights the lack of approved treatments. Quoin's investigational QRX003 is in a Phase 2/3 trial, with interim results showing statistical significance.Stock TitanQuoin Pharmaceuticals releases Netherton Syndrome videoQuoin Pharmaceuticals released a NETHERTON NOW video featuring a family with Netherton Syndrome and pediatric dermatologist Moise Levy. The company expects full recruitment for its QRX003 Phase 2/3 study by end of 2026, with topline data in Q2 2027. The video highlights the disease's impact on daily life and calls for public education.Business & FinancialQuoin Pharmaceuticals Provides Corporate Update And Reports Third Quarter 2026 Financial ResultsQuoin Pharmaceuticals reported Q3 2026 results, including positive interim data from its Phase 2/3 study of QRX003 in Netherton Syndrome, where 66.7% of six participants met the primary endpoint. The company also raised up to $50 million in a private placement and received FDA designations for QRX003 in Peeling Skin Syndrome. It expects to complete recruitment by year-end and report topline data in Q2 2027.Stock TitanQuoin QRX003 Netherton Trial Interim Data Meet EndpointsQuoin Pharmaceuticals reported positive interim data from its Phase 2/3 study of QRX003 in Netherton Syndrome, with primary and key secondary endpoints achieving statistical significance. The company also announced a private placement of up to $50 million and regulatory designations for QRX003 in Peeling Skin Syndrome. It expects to complete recruitment by year-end and report topline data in Q2 2027.Stock TitanQuoin Pharmaceuticals plans Q3 results release Nov. 5Quoin Pharmaceuticals plans to release its third-quarter 2026 financial results and a corporate update before market opening on November 5, 2026. The announcement will include operational highlights and financial figures for the quarter ended September 30, 2026.GlobeNewswireQuoin Pharmaceuticals to Announce Corporate Update and Third Quarter 2026 Financial Results on Thursday, November 5, 2026Quoin Pharmaceuticals will announce a corporate update and its third-quarter 2026 financial results before market open on November 5, 2026. The update will cover operational highlights and financial figures for the quarter ended September 30, 2026.Ticker ReportQuoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX) Sees Large Decrease in Short InterestQuoin Pharmaceuticals' short interest fell 69.1% to 20,231 shares as of October 15th. Analysts rate the stock a Moderate Buy with a consensus target of $17.33, while insiders bought 57,370 shares in the last 90 days. The company's lead program is QRX003 for Netherton syndrome.